Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 1
1990 1
1992 1
1993 3
1995 3
1997 2
1998 2
2001 3
2002 4
2003 4
2004 5
2005 10
2006 7
2007 7
2008 5
2009 9
2010 8
2011 14
2012 15
2013 16
2014 12
2015 19
2016 21
2017 25
2018 30
2019 38
2020 44
2021 16
Text availability
Article attribute
Article type
Publication date

Search Results

304 results
Results by year
Filters applied: . Clear all
Page 1
Idiopathic pulmonary fibrosis.
Richeldi L, Collard HR, Jones MG. Richeldi L, et al. Lancet. 2017 May 13;389(10082):1941-1952. doi: 10.1016/S0140-6736(17)30866-8. Epub 2017 Mar 30. Lancet. 2017. PMID: 28365056 Review.
Idiopathic pulmonary fibrosis.
Martinez FJ, Collard HR, Pardo A, Raghu G, Richeldi L, Selman M, Swigris JJ, Taniguchi H, Wells AU. Martinez FJ, et al. Among authors: richeldi l. Nat Rev Dis Primers. 2017 Oct 20;3:17074. doi: 10.1038/nrdp.2017.74. Nat Rev Dis Primers. 2017. PMID: 29052582 Review.
Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Flaherty KR, Wells AU, Cottin V, Devaraj A, Walsh SLF, Inoue Y, Richeldi L, Kolb M, Tetzlaff K, Stowasser S, Coeck C, Clerisme-Beaty E, Rosenstock B, Quaresma M, Haeufel T, Goeldner RG, Schlenker-Herceg R, Brown KK; INBUILD Trial Investigators. Flaherty KR, et al. Among authors: richeldi l. N Engl J Med. 2019 Oct 31;381(18):1718-1727. doi: 10.1056/NEJMoa1908681. Epub 2019 Sep 29. N Engl J Med. 2019. PMID: 31566307 Clinical Trial.
Idiopathic pulmonary fibrosis: pathogenesis and management.
Sgalla G, Iovene B, Calvello M, Ori M, Varone F, Richeldi L. Sgalla G, et al. Among authors: richeldi l. Respir Res. 2018 Feb 22;19(1):32. doi: 10.1186/s12931-018-0730-2. Respir Res. 2018. PMID: 29471816 Free PMC article. Review.
Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper.
Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, Goldin JG, Hansell DM, Inoue Y, Johkoh T, Nicholson AG, Knight SL, Raoof S, Richeldi L, Ryerson CJ, Ryu JH, Wells AU. Lynch DA, et al. Among authors: richeldi l. Lancet Respir Med. 2018 Feb;6(2):138-153. doi: 10.1016/S2213-2600(17)30433-2. Epub 2017 Nov 15. Lancet Respir Med. 2018. PMID: 29154106 Free article. Review.
Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, Lee JS, Maher TM, Wells AU, Antoniou KM, Behr J, Brown KK, Cottin V, Flaherty KR, Fukuoka J, Hansell DM, Johkoh T, Kaminski N, Kim DS, Kolb M, Lynch DA, Myers JL, Raghu G, Richeldi L, Taniguchi H, Martinez FJ. Collard HR, et al. Among authors: richeldi l. Am J Respir Crit Care Med. 2016 Aug 1;194(3):265-75. doi: 10.1164/rccm.201604-0801CI. Am J Respir Crit Care Med. 2016. PMID: 27299520 Free article. Review.
Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities.
George PM, Spagnolo P, Kreuter M, Altinisik G, Bonifazi M, Martinez FJ, Molyneaux PL, Renzoni EA, Richeldi L, Tomassetti S, Valenzuela C, Vancheri C, Varone F, Cottin V, Costabel U; Erice ILD working group. George PM, et al. Among authors: richeldi l. Lancet Respir Med. 2020 Sep;8(9):925-934. doi: 10.1016/S2213-2600(20)30355-6. Lancet Respir Med. 2020. PMID: 32890499
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR; INPULSIS Trial Investigators. Richeldi L, et al. N Engl J Med. 2014 May 29;370(22):2071-82. doi: 10.1056/NEJMoa1402584. Epub 2014 May 18. N Engl J Med. 2014. PMID: 24836310 Free article. Clinical Trial.
Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Raghu G, et al. Among authors: richeldi l. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST. Am J Respir Crit Care Med. 2018. PMID: 30168753
Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Wells AU, Flaherty KR, Brown KK, Inoue Y, Devaraj A, Richeldi L, Moua T, Crestani B, Wuyts WA, Stowasser S, Quaresma M, Goeldner RG, Schlenker-Herceg R, Kolb M; INBUILD trial investigators. Wells AU, et al. Among authors: richeldi l. Lancet Respir Med. 2020 May;8(5):453-460. doi: 10.1016/S2213-2600(20)30036-9. Epub 2020 Mar 5. Lancet Respir Med. 2020. PMID: 32145830 Clinical Trial.
304 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page